phenylephrine-hydrochloride and Parasitic-Diseases--Animal

Despite morphological differences of eggs and adults, Capillaria boehmi infections have been occasionally misdiagnosed as C. aerophila infections in the past. Capillaria boehmi is found in the nasal and paranasal sinuses of wild canids and dogs, which may suffer from nasal discharge, sneezing, epistaxis and, importantly, their scent can be impaired. In this study we present three challenging cases of nasal capillariosis in dogs, report and review the variable success of anthelmintic treatments and investigate C. boehmi prevalence in Swiss red foxes, considered as potential wild life reservoir. Out of two females and one male dog (all scent hounds, aged 3-9 years and weighing 19-31 kg), two dogs were previously coproscopically misdiagnosed with Trichuris infections. Two dogs showed clinical signs such as sneezing, coughing and impaired scent. From one dog adult living C. boehmi were obtained by nasal lavage. The identity of worms and eggs of all three dogs were genetically confirmed (18S rRNA, 100 % identity in 578 base pairs). Dogs 1-3 were followed-up for overall 54, 8, and 67 months, respectively. All dogs repeatedly excreted C. boehmi eggs in faecal samples despite treatments with the following compounds, in various dosage and retreatment protocols: fenbendazole, milbemycin oxime (orally), moxidectin/imidacloprid/ (spot-on) and levamisole (intramuscularly). The different anthelmintic compounds showed variable success regarding their effect on clinical outcome and on stopping egg excretion. Reinfections due to a contaminated environment could not be fully excluded. In winter 2016 and 2017, 218 foxes from the canton of Zurich, Switzerland, were examined. Tissues of nasal and paranasal sinuses were investigated for adult Capillaria specimens and eggs. We describe for the first time C. boehmi infections in Switzerland, observing a high prevalence (190/218, 87.2 %). Overall, 107 of 126 adults (84.9 %, 95 % Confidence Interval, CI: 77.5-90.7 %) and 83 of 92 youngsters (90.2 %, CI: 82.2-95.4 %) were infected. The presence of C. boehmi did not correlate with age (P = 0.209), but correlated significantly with sex: male foxes (102 of 107, 95.3 %, CI: 89.4-98.5 %) were significantly (P = 0.001) more often infected than females (88 of 111, 79.3 %, CI: 70.5-86.4 %). Worm burden ranged from 1 to 72 adult specimens (geometric mean: 5.7). In conclusion, C. boehmi infections can be mis- and/or underdiagnosed in dogs. Appropriate anthelmintic treatments, preventing copr

Topics: Animals; Capillaria; Dog Diseases; Dogs; Enoplida Infections; Female; Foxes; Male; Nose; Parasitic Diseases, Animal; Prevalence; Switzerland

To investigate the therapeutic and prophylactic efficacy of an ivermectin controlled-release capsule against nasal bots (Oestrus ovis) in sheep.. Trial 1--A pen study with controls. Trial 2--A field study with controls.. Trial 1--Forty Merino wethers with natural infestations of nasal bot were used. Trial 2--One hundred nasal bot-free wethers were used.. Trial 1--Ten randomly selected animals were slaughtered and the heads split and examined to confirm bot infestation. Fifteen animals were allocated to untreated controls and 15 to treatment with a controlled-release capsule delivering ivermectin at > or = 20 micrograms/kg/day for 100 days. Twenty-nine days after treatment the sheep were killed and examined for nasal bots. Trial 2--Nasal bot-free sheep were allocated to two groups of 45 animals. One group was untreated the other sheep were treated with capsules as above. The sheep were grazed as a single group exposed to natural challenge from O ovis. Ninety days after treatment the animals were slaughtered and examined for nasal bot infestation.. Trial 1--Live O ovis larvae were recovered from 60% of control sheep. No live larvae were collected from treated sheep. Trial 2--Forty-one percent of untreated sheep harbored nasal bot infestations. No live larvae were collected from any treated animal.. Treatment with a single ivermectin controlled release capsule was 100% effective against existing infestations of O ovis and as a prophylactic treatment for this parasite.

Topics: Animals; Capsules; Delayed-Action Preparations; Diptera; Insecticides; Ivermectin; Male; Myiasis; New South Wales; Nose; Parasitic Diseases; Parasitic Diseases, Animal; Sheep; Sheep Diseases

A two-year-old, female neutered, cross-breed dog imported from Romania was diagnosed with nasal infestation of Linguatula serrata after she sneezed out an adult female. The dog was presented with mucopurulent/sanguinous nasal discharge, marked left-sided exophthalmia, conjunctival hyperaemia and chemosis. Computed tomography and left frontal sinusotomy revealed no further evidence of adult parasites. In addition, there was no evidence of egg shedding in the nasal secretions or faeces. Clinical signs resolved within 48 hours of sinusotomy, and with systemic broad-spectrum antibiotics and non-steroidal anti-inflammatory drugs. Recommendations are given in this report regarding the management and follow-up of this important zoonotic disease.

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiparasitic Agents; Dog Diseases; Dogs; Female; Nose; Parasitic Diseases, Animal; Pentastomida; Romania; Sinusitis; United Kingdom

Cydectin(®) 2% LA Solution for Injection for Sheep (Pfizer Animal Health) is a long-acting (LA) formulation of moxidectin for the treatment and prevention of mixed infections of gastro-intestinal nematodes, respiratory nematodes and certain arthropod parasites in sheep. To evaluate the duration of persistent efficacy against nasal bots (Oestrus ovis), a natural exposure study was conducted in Spain during the summer of 2011. One hundred and twenty nasal bot-free, Rasa Aragonesa sheep were randomly allocated to eight groups of 15 animals each. On Day 0, four groups were treated at the recommended dose rate of 1 mg moxidectin/kg bodyweight. Four groups remained untreated as negative controls. All animals were held in nasal bot-proof housing except for exposure to natural challenge when one group of treated sheep and one of group of control animals were transferred to a local pasture at either 0-20, 20-40, 40-60, or 60-80 days after treatment. Following challenge, sheep were scored for clinical signs of bot infestation, necropsied and the heads sectioned for larval recovery. Nasal bot larvae were retrieved from 7 to 11 control sheep following each exposure period indicating that adult bots were active throughout the study. In the first challenge up to 20 days after treatment, when sheep were slaughtered immediately after exposure, the majority of larvae were first instar (L1) and only 3 of the 15 control sheep were infested with second instars (L2). There was 100% efficacy against L2 and 38.1% reduction in the number of live L1 in the treated sheep but mean counts were not significantly different between treatment and control groups (P ≥ 0.05). For the subsequent exposure periods 20-80 days after treatment (necropsies 7-9 days after challenge), 6-10 sheep were infested with L1 and 9-11 control sheep were infested with L2 and third instars (L3). There was negligible efficacy against L1, but treatment with moxidectin resulted in 100% control of L2 and L3. These results are consistent with the biology of nasal bots and control with a systemic agent, as the slower growing L1 have limited feeding and are therefore less susceptible to systemic parasiticides. The study demonstrated that the persistent efficacy of this long-acting injectable formulation of moxidectin protects against the development of active O. ovis infestations for at least 80 days after treatment.

Topics: Animals; Delayed-Action Preparations; Diptera; Female; Injections; Insecticides; Larva; Macrolides; Myiasis; Nose; Parasitic Diseases, Animal; Random Allocation; Sheep; Sheep Diseases; Spain; Treatment Outcome